Ted W. Johnson

Ted W. Johnson

Auto-generated profile, based on publicly available information

Ted W. Johnson

Oncology Medicinal Chemistry, Pfizer Worldwide Research and Development, 10770 Science Center Drive, La Jolla, California 92121, United States

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2016 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ASAlice T. Shaw
Alice T. Shaw
LFLuc Friboulet
Luc Friboulet
ILIgnaty Leshchiner
Ignaty Leshchiner
JGJustin F. Gainor
Justin F. Gainor
SBSimon Bergqvist
Simon Bergqvist
JEJeffrey A. Engelman
Jeffrey A. Engelman
In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain. This mutation is predicted to result in a substitution of cysteine by tyrosine at amino acid residue 1156 (C1156Y). Her tumor did not respond to a second-generation ALK inhibitor, but it did respond to lorlatinib (PF-06463922), a third-generation inhibitor. When her tumor relapsed, sequencing of the resistant tumor revealed an ALK L1198F mutation in addition to the C1156Y mutation. The L1198F substitution confers resistance to lorlatinib through steric interference with drug binding. However, L1198F paradoxically enhances binding to crizotinib, negating the effect of C1156Y and resensitizing resistant cancers to crizotinib. The patient received crizotinib again, and her cancer-related symptoms and liver failure resolved. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT01970865.)

1 October 2009 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
TJTed W. Johnson
Ted W. Johnson
KDKlaus R. Dress
Klaus R. Dress
MEMartin Edwards
Martin Edwards

28 March 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TJTed W. Johnson
Ted W. Johnson
RGRebecca A. Gallego
Rebecca A. Gallego
MEMartin P. Edwards
Martin P. Edwards

8 March 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JLJessica J. Lin
Jessica J. Lin
NCNoura J. Choudhury
Noura J. Choudhury
SYSatoshi Yoda
Satoshi Yoda
VZViola W. Zhu
Viola W. Zhu
TJTed W. Johnson
Ted W. Johnson
JGJustin F. Gainor
Justin F. Gainor
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma kinase/ROS1 inhibitor, recently demonstrated efficacy in ROS1+ NSCLC, including in crizotinib-pretreated patients. However, mechanisms of lorlatinib resistance in ROS1+ disease remain poorly understood. Here, we assessed mechanisms of resistance to crizotinib and lorlatinib. Experimental Design: Biopsies from patients with ROS1+ NSCLC progressing on crizotinib or lorlatinib were profiled by genetic sequencing. Results: From 55 patients, 47 post-crizotinib and 32 post-lorlatinib biopsies were assessed. Among 42 post-crizotinib and 28 post-lorlatinib biopsies analyzed at distinct timepoints, ROS1 mutations were identified in 38% and 46%, respectively. ROS1 G2032R was the most commonly occurring mutation in approximately one third of cases. Additional ROS1 mutations included D2033N (2.4%) and S1986F (2.4%) post-crizotinib and L2086F (3.6%), G2032R/L2086F (3.6%), G2032R/S1986F/L2086F (3.6%), and S1986F/L2000V (3.6%) post-lorlatinib. Structural modeling predicted ROS1L2086F causes steric interference to lorlatinib, crizotinib, and entrectinib, while it may accommodate cabozantinib. In Ba/F3 models, ROS1L2086F, ROS1G2032R/L2086F, and ROS1S1986F/G2032R/L2086F were refractory to lorlatinib but sensitive to cabozantinib. A patient with disease progression on crizotinib and lorlatinib and ROS1 L2086F received cabozantinib for nearly 11 months with disease control. Among lorlatinib-resistant biopsies, we also identified MET amplification (4%), KRAS G12C (4%), KRAS amplification (4%), NRAS mutation (4%), and MAP2K1 mutation (4%). Conclusions: ROS1 mutations mediate resistance to crizotinib and lorlatinib in more than one third of cases, underscoring the importance of developing next-generation ROS1 inhibitors with potency against these mutations, including G2032R and L2086F. Continued efforts are needed to elucidate ROS1-independent resistance mechanisms.

6 February 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
QHQinhua Huang
Qinhua Huang
TJTed W. Johnson
Ted W. Johnson
SBSimon Bailey
Simon Bailey
ABAlexei Brooun
Alexei Brooun
KBKevin D. Bunker
Kevin D. Bunker
MEMartin P. Edwards
Martin P. Edwards
Crizotinib (1), an anaplastic lymphoma kinase (ALK) receptor tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration in 2011, is efficacious in ALK and ROS positive patients. Under pressure of crizotinib treatment, point mutations arise in the kinase domain of ALK, resulting in resistance and progressive disease. The successful application of both structure-based and lipophilic-efficiency-focused drug design resulted in aminopyridine 8e, which was potent across a broad panel of engineered ALK mutant cell lines and showed suitable preclinical pharmacokinetics and robust tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).

20 March 2023 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
RGRebecca A. Gallego
Rebecca A. Gallego
LBLouise Bernier
Louise Bernier
HCHui Chen
Hui Chen
SCSujin Cho-Schultz
Sujin Cho-Schultz
LCLoanne Chung
Loanne Chung
SNSajiv K. Nair
Sajiv K. Nair